epithelial cells, and HTLV-I infection can modify the functions of these cells (4) (5) (6) . In this context, a previous study by our group that was conducted in an area endemic for HTLV-I infection showed that HTLV-I-positive patients with RA are more resistant to TNF inhibitors compared with HTLV-I-negative RA patients (7) .
One case of ATL was reported to have occurred 27 months after the initiation of adalimumab for the treatment of spondyloarthritis (8) . Although TNF inhibitor treatment had no effect on proliferation of an HTLV-Iinfected cell line in vitro (9) , it has not been established whether TNF inhibitors affect the HTLV-I infection status, including the occurrence of ATL or HAM/TSP. In addition, the precise ability of TNF inhibitors to decrease disease activity under inflammatory conditions, such as in the presence of high levels of TNF or interleukin-6 (IL-6), also has not been determined in patients with HTLV-I infection. Since TNF inhibitors have become a first-line biologic disease-modifying antirheumatic drug (DMARD) treatment in clinical practice, it is crucial to determine their efficacy and safety in HTLV-I-positive RA patients, especially in areas endemic for HTLV-I infection.
In a previous study by our group (7), we compared the response to TNF inhibitors in 10 HTLV-Ipositive RA patients with that in 20 HTLV-I-negative patients with RA (matched for age and sex), in a single area with a high prevalence of HTLV-I, Miyazaki Prefecture. We observed that the treatment outcomes were generally affected by several background elements, such as disease activity at the start of treatment and positivity for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPAs). However, we were unable to evaluate the confounding factors due to the limited number of cases. In the current study, therefore, we attempted to resolve this problem by including all of the RA patients for whom TNF inhibitors were newly introduced as a first biologic DMARD during the study period and performed multivariable analyses to examine and confirm the genuine effects of HTLV-I on TNF inhibitor treatment of RA patients in multiple hospitals in the Nagasaki and Miyazaki Prefectures in Japan, which are known as areas endemic for HTLV-I infection.
PATIENTS AND METHODS
Study design. This was a retrospective cohort study in patients with RA with or without anti-HTLV-I antibodies who were treated with TNF inhibitors in Nagasaki Prefecture and Miyazaki Prefecture in Japan, which are known as areas endemic for HTLV-I infection (10) .
Patients. We reviewed the cases of all RA patients in whom TNF inhibitors were newly introduced as a first biologic DMARD between June 2001 and June 2013 at hospitals in Nagasaki Prefecture and Miyazaki Prefecture. RA patients who were switched from a biologic DMARD to a TNF inhibitor were excluded. All patients fulfilled the American College of Rheumatology (ACR) 1987 revised criteria for the classification of RA (11) and/or the ACR/European League Against Rheumatism (EULAR) 2010 classification criteria for RA (12) . All of the patients included in our previous study (7) were excluded. A final total of 585 patients with RA were included in the study.
This study was approved by the Institutional Review Board of Nagasaki University Hospital (NU120087), the Research Ethics Committee of the University of Miyazaki (no. 859), and the Research Ethics Committees of Isahaya General Hospital (approved July 7, 2012), Sasebo Chuo Hospital (no. 2016-23), Nagasaki Medical Hospital of Rheumatology (approved February 20, 2013) , and Zenjinkai Shimin-no-Mori Hospital (approved August 20, 2012) . Informed consent for the use of their data was obtained from some of the patients, and an opt-out strategy was chosen for the rest of the patients.
Data collection. Using the patients' medical records, we collected the demographic and clinical characteristics, laboratory data, treatments at entry, and therapeutic outcomes at 24 weeks.
Evaluations of the efficacy and safety of the TNF inhibitors. The clinical disease activity of RA in each patient was evaluated using the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) (13) at baseline (0 weeks) and at 24 weeks after the initiation of the TNF inhibitor treatment. For evaluation of the patients' responses to the treatments, the EULAR response criteria (14) were used. These criteria classify individual patients as having no response, a moderate response, or a good response depending on the extent of change in the DAS28-ESR and the achieved level of the DAS28-ESR. The primary end point was the EULAR response at the 24-week time point. The secondary end point was the change in the patients' DAS28-ESR between entry and the 24-week time point. For assessment of the safety of TNF inhibitor treatment, we determined the occurrence of ATL or HAM/TSP at the 24-week time point of treatment.
Time points of anti-HTLV-I antibody assay. HTLV-I antibody was measured using one of the conventional methods, i.e., either chemiluminescence immunoassay (Architect HTLV; Abbott), enzyme-linked chemiluminescence assay (Lumipulse Presto HTLV kit; Fujirebio), or a particle agglutination test (Serodia-HTLV-I kit; Fujirebio). The time point of anti-HTLV-I antibody assay differed among patients, with some examined before, some examined during, and some examined after the start of TNF inhibitor treatment. However, the anti-HTLV-I antibody status had been checked in all patients by January 2014.
Statistical analysis. We compared the baseline characteristics of the anti-HTLV-I antibody-positive (n = 50) and anti-HTLV-I antibody-negative (n = 535) RA patients. Categorical variables were described as frequencies and quantitative variables as the median and interquartile range. The association between variables was assessed using Fisher's exact test for categorical variables and Wilcoxon's rank sum test for quantitative variables. The paired t-test was used to detect differences in change in the DAS28-ESR achieved by TNF inhibitors between the anti-HTLV-I antibody-positive patients and the anti-HTLV-I antibody-negative patients. We used the Cochran-Armitage test to compare the trend of EULAR responses between anti-HTLV-I antibody-positive patients and anti-HTLV-I antibodynegative patients.
We performed a multiple mixed-effects regression analysis with a random hospital-specific intercept to determine factors that contribute to the EULAR response. Here, we defined the EULAR responses as none, moderate, and good. We included variables that exhibited a significant difference between the anti-HTLV-I antibody-positive and anti-HTLV-I antibody-negative groups. We excluded the type of TNF inhibitor as a variable, because all types of TNF inhibitors are equally suggested as the first biologic DMARDs in the EULAR recommendations (15) . In addition, we included clinically important variables in the model. Finally, we used age at entry, sex, anti-HTLV-I antibody positivity, ACPA status, concomitant use of methotrexate (MTX), concomitant use of prednisolone, the DAS28-ESR at entry, and the interaction term between anti-HTLV-I antibody positivity and ACPA status as fixed effects.
We analyzed change in the DAS28-ESR values from baseline to the 24-week time point, using a linear mixed-effects regression model with an unstructured residual covariance matrix for measurements within the hospital. Age at entry, sex, anti-HTLV-I antibody positivity, ACPA status, concomitant use of MTX, concomitant use of prednisolone, the DAS28-ESR at entry, and the interaction term between anti-HTLV-I antibody positivity and ACPA status were used as fixed effects. Subgroup analyses were performed to examine the effects of TNF inhibitors across ACPA status using the above multiple regressions (excluding ACPA status and interaction term), which were the complete case analyses. ACPA status was not available for 183 patients (31.3%).
Because complete case analyses can lead to a loss of power and biased results, we performed a multiple imputation analysis. To investigate variables associated with missing ACPA status, descriptive statistics and Fisher's exact test for categorical variables and Wilcoxon's rank sum test for quantitative variables were performed both in the cohort with missing ACPA status and in the cohort in which the ACPA status was not missing (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40461/abstract).
A logit model was used for imputation of ACPA status for age at entry, sex, hospital, disease duration, anti-HTLV-I antibody positivity, concomitant use of MTX, concomitant use of prednisolone, type of TNF inhibitor, persistence at 24 weeks, and EULAR response. Each of these variables in the logit model was consecutively selected as the dependent variable in the missing-data imputation of ACPA status and the variables considered to be related to the absence of data on ACPA status (P < 0.1). However, tender joint counts (28 joints assessed) at entry, ESR at entry, physician's global assessment at entry, Simplified Disease Activity Index (SDAI) (16) at entry, and Clinical Disease Activity Index (16) at entry were not included in the logit model, because these factors were strongly related to EULAR response and suspected of multicollinearity. We repeated the imputation 1,000 times, followed by application of Rubin's rule to combine the estimated parameters and standard errors.
All tests were 2-sided. P values less than 0.05 were considered significant. All statistical analyses were performed Table 1 . Demographic, clinical, and laboratory characteristics, treatments, and disease activity in the total patient group, anti-HTLV-I antibody-positive patients, and anti-HTLV-I antibody-negative patients at entry* 
RESULTS
Patient characteristics. Table 1 shows the demographic and clinical characteristics of the total group of patients, anti-HTLV-I antibody-positive patients, and anti-HTLV-I antibody-negative patients. Fifty (8.5%) of the 585 patients were anti-HTLV-I antibody-positive. Patients in the anti-HTLV-I antibody-positive group were significantly older at entry compared with the 535 anti-HTLV-I antibody-negative patients (64 years versus 59 years; P = 0.0024). Eighty-two percent of the patients were female, and the median disease duration was 69 months. Eighty-two percent of the total group of patients (n = 402 analyzed) were ACPA-positive.
The median DAS28-ESR was 5.21, which indicated high disease activity. Infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol were used as TNF inhibitors. There were no significant differences between the anti-HTLV-I antibody-positive and anti-HTLV-I antibody-negative groups in terms of the percentage of female patients, disease duration, RF positivity, ACPA positivity, frequency of MTX treatment, and frequency of prednisolone treatment at entry, or disease activity.
Overall efficacy and safety of the TNF inhibitors. The EULAR responses were significantly better in the HTLV-I-negative patients compared with the HTLV-Ipositive patients (P = 0.0277) ( Figure 1A) . The mean DAS28-ESR values were significantly decreased from 5.03 (anti-HTLV-I antibody-positive group) and 5.19 (anti-HTLV-I antibody-negative group) at entry to 3.62 and 3.39 at 24 weeks, respectively ( Figure 1B) . The decrease in the DAS28-ESR was significantly greater in the HTLV-I-negative patients compared with the HTLV-I-positive patients (P = 0.0378) ( Figure 1B ). In the total group, the persistence rate of TNF inhibitors at 24 weeks was 89%, and the rate did not differ significantly between the 2 patient groups ( Table 1) . None of the patients developed ATL or HAM/TSP during the 24 weeks of TNF inhibitor treatment.
Factors associated with the achievement of good and moderate responses. Among the factors age at entry, sex, anti-HTLV-I antibody positivity, ACPA positivity, concomitant MTX use at entry, concomitant prednisolone use at entry, and DAS28-ESR at entry, those that were significantly associated with good and moderate EULAR responses by the multiple mixed-effects regression analysis were anti-HTLV-I antibody positivity and the DAS28-ESR at entry in the overall patient group (odds ratio 0.24 and 1.70, respectively [P = 0.0407 and P < 0.0001, respectively]) ( Table 2 ). .0% had a good European League Against Rheumatism response, 34.0% had a moderate response, and 34.0% had no response. Among the anti-HTLV-I antibody-negative patients, 38.3% had a good response, 42.4% had a moderate response, and 19.3% had no response. Thus, the responses in the anti-HTLV-I antibody-negative patients were significantly better than those in the anti-HTLV-I antibody-positive patients (P = 0.0277). B, The Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) decreased significantly, from a mean AE SD of 5.03 AE 1.44 in anti-HTLV-I antibody-positive patients and 5.19 AE 1.33 in anti-HTLV-I antibody-negative patients at entry to 3.62 AE 1.49 and 3.39 AE 1.33, respectively, at 24 weeks. Anti-HTLV-I antibody-positive patients had a smaller change in the DAS28-ESR compared with anti-HTLV-I antibody-negative patients (P = 0.0378). C, Among the anti-citrullinated protein antibody (ACPA)-positive patients, there was no significant difference in change in the DAS28-ESR between the anti-HTLV-I antibody-positive patients and the anti-HTLV-I antibody-negative patients (mean AE SD 1.42 AE 1.46 and 1.84 AE 1.37, respectively [P = 0.5464]). D, Among the ACPA-negative patients, change in the DAS28-ESR was significantly greater in the anti-HTLV-I antibody-negative patients compared with the anti-HTLV-I antibody-positive patients (mean AE SD 1.81 AE 1.13 and 0.75 AE 1.51, respectively [P = 0.0088]). P values in C and D were calculated using linear mixed-effects regression analysis, including age at entry, sex, anti-HTLV-I antibody positivity, concomitant methotrexate use at entry, concomitant prednisolone use at entry, and DAS28-ESR at entry, as shown in Table 2 . Table 2) but not in the ACPA-positive patients. When the patients were divided into RF-positive and RF-negative groups, there was no significant difference in the EULAR response rates between the 2 groups (data not shown).
Factors associated with change in the DAS28-ESR. Among the factors age at entry, sex, anti-HTLV-I antibody positivity, ACPA positivity, concomitant MTX use at entry, concomitant prednisolone use at entry, and the DAS28-ESR at entry, those that were significantly associated with change in the DAS28-ESR, as determined by linear mixedeffects regression analysis, were sex (change in men compared with change in women), anti-HTLV-I antibody positivity, concomitant prednisolone use at entry, and the DAS28-ESR at entry in the overall patient group (coefficients 0.4103, -0.8613, -0.1915, and 0.5169, respectively [P = 0.0007, P = 0.0152, P = 0.0479, and P < 0.0001, respectively]) ( Table 2) .
The effects of differences in anti-HTLV-I antibody status in ACPA-positive patients and ACPA-negative patients were examined ( Figures 1C and D) , with exclusion of confounding effects between anti-HTLV-I antibody status and ACPA status. Within the ACPA-positive group, there was no significant difference in change in the DAS28-ESR between the HTLV-I-positive and HTLV-I-negative patients ( Figure 1C ), but in the ACPA-negative group, the HTLV-I-negative patients had a significantly greater change in the DAS28-ESR compared with the HTLV-I-positive patients (P = 0.0088) ( Figure 1D ) in the linear mixed regression analysis including age at entry, sex, anti-HTLV-I antibody positivity, concomitant MTX use at entry, concomitant prednisolone use at entry, and the DAS28-ESR at entry ( Table 2) .
Evaluation of calendar time effects. To evaluate the calendar time effect, we divided patients into 2 groups: Supplementary Table 3 ).
DISCUSSION
The current study, which was conducted in an area endemic for HTLV-I infection, revealed independent variables at entry that can be used to predict the clinical efficacy of TNF inhibitors for treating RA patients. As reported previously, we observed that the DAS28 at entry and sex are associated with improvement in the DAS28. S€ oderlin et al demonstrated that a high DAS28 at entry indicates a better SDAI response to treatment in patients treated with their first anti-TNF drug (17) , which is consistent with our findings in the current study. Regarding sex, a previous investigation indicated that female sex may be an independent predictor of being treatment-resistant for remission both in patients with early-stage RA and in those with established RA (18) . Although the baseline characteristics as well as the treatment regimens in the current study were different from those in the above-mentioned reports, our current data are consistent with previous observations. In consideration of the above-described results, the overall baseline characteristics and the clinical responses of the study population in the current study may not be very different from those observed in the previous studies.
The most intriguing point of the current study is that we were able to compare the effects of TNF inhibitors between HTLV-I-positive and HTLV-I-negative patients. The difference in the effects of TNF inhibitors as related to HTLV-I is quite meaningful in light of the inflammation that might be caused by HTLV-I and the pathogenesis of arthritis. In particular, the attenuated effectiveness of TNF inhibitors suggests that HTLV-I infection may cause inflammation through cytokines, excluding TNF.
Some studies have shown a relationship between inflammation and HTLV-I infection. It was previously reported that HTLV-I-infected Tcells induced the production of interferon-c (IFNc) (9, 19) and IL-6 in addition to TNF (9) . Besides infecting T cells, HTLV-I infects synovial fibroblasts (5) and CD68+ macrophages (20) and enhances the production of cytokines. Theses cytokines include TNF (5, 20) and IL-1a (5). Clinically, patients with HAM/TSP have been reported to show high circulating levels of TNFand IL-2-secreting HTLV-I-specific CD4+ T cells (21) . Based on these reports, it appears that the proinflammatory status of HTLV-I-infected patients, particularly characterized by the presence of IFNc, IL-6, IL-1a, and IL-2, may attenuate the effectiveness of TNF inhibitors.
It is worth noting that another study by our group showed a high seroprevalence (20.4%) of anti-HTLV-I antibody in RA patients living in an area in Nagasaki Prefecture that is endemic for HTLV-I infection (22) . Thus, a second possibility to consider is that HTLV-I infection itself might be directly involved in the pathologic process in RA. In that previous study (22) , we observed no significant differences in clinical and laboratory findings, including RF status, between HTLV-I-positive and HTLV-Inegative RA patients, but we demonstrated for the first time, using subanalysis, that the resistance to TNF inhibitors among HTLV-I-positive RA patients was present in the ACPA-negative subgroup and not in the ACPA-positive subgroup.
It is generally accepted that the clinical response of ACPA-negative RA patients to TNF inhibitors is better than or equivalent to that of ACPA-positive RA patients (23) in areas where HTLV-I infection is not endemic. Consistent with the observations in our previous investigation (22) , in the current study we observed no significant difference in the presence or absence of RF between HTLV-Ipositive and HTLV-I-negative RA patients. A low response to TNF inhibitor treatment in ACPA-negative patients with HTLV-I antibodies is a new characteristic finding, although it is important to note that only a small number of ACPA-negative patients with anti-HTLV-I antibodies were included; specifically, 11 of our 71 ACPA-negative patients were positive for anti-HTLV-I antibodies.
Because there is some difference in genetic predisposition between ACPA-negative RA patients and ACPApositive RA patients (24) , the network of inflammatory cytokines might be different between these 2 groups. Because IL-6-driven CD4+ T cell activation via STAT-3 is reported to be a feature of ACPA-negative RA (25) , foregoing IL-6 production by HTLV-I-infected cells in ACPA-negative RA patients may attenuate the effectiveness of TNF inhibitors in ACPA-negative patients with anti-HTLV-I antibody positivity.
The lifetime risks for the occurrence of ATL or HAM/TSP in HTLV-I-infected patients are estimated to be 2.5-5% or 0.3-2%, respectively (26) . Although these risks are not very high, ATL and HAM/TSP are lifethreatening diseases, and thus the development of ATL or HAM/TSP in HTLV-I-positive patients is a critical matter. There were no occurrences of ATL or HAM/TSP during the 24 weeks of TNF inhibitor treatment in the current study, which might serve as a short-term safety profile for TNF inhibitors in areas endemic for HTLV-I infections. A previous study analyzed the response to treatment with TNF inhibitors and change in HTLV-I markers, such as proviral load and clonality of HTLV-Iinfected cells, in 2 patients with RA and revealed no significant change in either of these patients (27) .
Our study has some limitations. First, we could not evaluate the long-term outcomes for efficacy and safety. The efficacy of biologic DMARDs, including TNF inhibitors, may be attenuated over time (28) , and the 24-week observational results of the current study may not precisely reflect the real efficacy of TNF inhibitors in HTLV-I-positive RA patients compared with HTLV-I-negative RA patients. In addition, proviral load is known to be a clinically useful marker in ATL (29) and HAM/TSP (30) . However, due to the relatively low prevalence of ATL and HAM/TSP, longterm follow-up with more patient-years along with HTLV-I markers will also be needed to account for the risk of these diseases.
The efficacy of TNF inhibitors was attenuated when these agents were used to treat anti-HTLV-I antibody-positive patients, especially among the ACPA-negative patients. Although TNF inhibitors may not increase the risks of ATL and HAM/TSP, the long-term efficacy and safety of TNF inhibitors must be further examined.
